Two Independent Review Boards Join the WIRB-Copernicus Group
Aspire IRB and Midlands IRB become part of the WCG family, further expanding its geographic and program reach
The WIRB-Copernicus Group ("WCG"), the world's largest provider of regulatory and ethical review services for clinical research, announced today that two independent review boards (IRBs) – Aspire IRB and Midlands IRB – have joined the Group. Located near San Diego, CA and Kansas City, MO, respectively, these companies expand WCG's presence in two major clinical research hubs. The addition of Midlands IRB and Aspire IRB also increases the Group's expertise in Early Phase (I & II) reviews.
WCG's Chairman and CEO Donald A. Deieso, Ph.D., commented, "We are delighted to welcome Midlands and Aspire to our family; these two high quality organizations bring with them exceptional people, outstanding regulatory and compliance records, and strong client relationships. Both Midlands and Aspire will continue to operate independently and will retain their leadership, personnel, and brands. We look forward to providing both organizations with expanded access to leading technology, capital, and corporate support which will assure that they continue to deliver superior services to their clients."
As members of the WCG family, Midlands IRB and Aspire IRB will have access to WCG's significant resources, including state-of-the-art technology, industry-leading advisory panels, and rigorous quality management and compliance programs.
"We are thrilled to bring to bear all of the resources of the WIRB-Copernicus Group to ensure the highest standards of human subject protection for our clients," said Michele R. Baptista, CIP, president of Aspire IRB. "Not only will we continue to provide the hands-on, personalized interaction that our clients have come to expect – and is so necessary in Early Phase research – but we will also be able to offer them more advanced technologies and services to facilitate the optimization of Late Phase (III & IV) research, such as electronic informed consent, learning management and accelerated study start-up solutions."
Midlands IRB and Aspire IRB join Western IRB (WIRB), Copernicus Group IRB, and IRBNet as members of the WCG family of companies, which now includes 12 individual AAHRPP-accredited panels, three of which are focused on the review of oncology research.
Financial details about the transactions were not disclosed.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
